Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced its 2025 interim report for the period ending June 30, 2025. The company plans to distribute an interim cash dividend of RMB0.40 per share, totaling RMB650,316,379.60. This decision reflects the company’s commitment to returning value to its shareholders. The financial reports were prepared according to China Accounting Standards and were unaudited.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$21.70 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company with limited liability established in the People’s Republic of China. The company operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products.
Average Trading Volume: 1,599,749
Technical Sentiment Signal: Buy
Current Market Cap: HK$45B
For an in-depth examination of 0874 stock, go to TipRanks’ Overview page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money